Cipla Limited (NSEI: CIPLA)
Health Care · Pharmaceuticals · IN
Rs1,301.00
-3.20% today · -16.7% 1Y
Cipla Limited (NSEI: CIPLA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $10.86B and employs 31,369 people.
Over the last twelve months the share price has lost 16.7%, trading between 1.17K and 1.67K.
Tweenvest scores Cipla Limited across four factors: quality 85/100, value 45/100, growth 40/100, dividend 21/100. Its strongest factor is quality.
CIPLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.86B
- Revenue (TTM)
- $2.97B
- P/E
- 31.20
- EPS
- 41.70
- Dividend yield
- 1.00%
- Beta (5Y)
- 0.09
- 52-week high
- Rs1,673.00
- 52-week low
- Rs1,165.70
- Avg volume (3M)
- —
- Shares outstanding
- 807.85M
- Employees
- 31,369
- Next earnings
- —
About Cipla Limited
Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
- ISIN
- INE059A01026
- Founded
- 1935
- Listed since
- Jan 1, 1996
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Recordati Industria Chimica e Farmaceutica S.p.A.BIT: REC | $12.15B | €52.95 | -0.09% |
| Zydus Lifesciences LimitedNSEI: ZYDUSLIFE | $11.52B | Rs1,117.50 | -2.46% |
| Elanco Animal Health IncorporatedNYSE: ELAN | $11.45B | $22.78 | -0.61% |
| Laurus Labs LimitedNSEI: LAURUSLABS | $11.37B | Rs2,036.60 | +2.65% |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.SHSE: 600436 | $10.79B | CN¥119.82 | +1.38% |
| Dr. Reddy's Laboratories LimitedBSE: 500124 | $10.29B | Rs1,195.10 | +1.28% |
| Mankind Pharma LimitedNSEI: MANKIND | $10.11B | Rs2,368.50 | -6.57% |
| Haisco Pharmaceutical Group Co., Ltd.SZSE: 002653 | $10.11B | CN¥61.02 | -1.87% |
Figures last refreshed Oct 11, 2026.